These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 6861864)

  • 1. Pharmacokinetics of prenalterol after single and multiple administration of controlled release tablets to patients with congestive heart failure.
    Dahlström U; Graffner C; Jonsson U; Hoffmann KJ; Karlsson E; Lagerström PO
    Eur J Clin Pharmacol; 1983; 24(4):495-502. PubMed ID: 6861864
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacokinetics of prenalterol in healthy subjects and patients with congestive heart failure.
    Rönn O
    Acta Med Scand Suppl; 1982; 659():89-98. PubMed ID: 6127901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of prenalterol in congestive heart failure.
    Hjalmarson A; Abelardo N; Waagstein E
    Eur Heart J; 1982 Dec; 3 Suppl D():115-21. PubMed ID: 7160397
    [No Abstract]   [Full Text] [Related]  

  • 4. Short and long-term effects of hydralazine and combined hydralazine and prenalterol therapy in patients with congestive heart failure.
    Drexler H; Löllgen H; Just H
    Acta Med Scand Suppl; 1982; 659():315-24. PubMed ID: 6127898
    [No Abstract]   [Full Text] [Related]  

  • 5. Intravenous and oral prenalterol in congestive heart failure. Effects on systemic and coronary hemodynamics and myocardial catecholamine balance.
    Wahr DW; Swedberg K; Rabbino M; Hoyle MJ; Curran D; Parmley WW; Chatterjee K
    Am J Med; 1984 Jun; 76(6):999-1005. PubMed ID: 6731471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of prenalterol administered orally in patients with congestive heart failure.
    Hjalmarson A; Abelardo N; Caidahl K; Reyes C; Waagstein F; Wallentin I; Wikstrand J; Estrada-Yamamoto M
    Acta Med Scand Suppl; 1982; 659():201-20. PubMed ID: 6127890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prenalterol, an oral beta-1 adrenoceptor agonist, in the treatment of chronic heart failure.
    Sharpe DN; Coxon R
    Eur J Clin Pharmacol; 1983; 25(4):539-45. PubMed ID: 6653650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pharmacokinetics of oral and intravenous prenalterol in young, healthy volunteers.
    Clarke AF; Jack DB; Kendall MJ; Smith SR
    Biopharm Drug Dispos; 1986; 7(1):47-52. PubMed ID: 3955199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute intravenous and sustained oral treatment with the beta1 agonist prenalterol in patients with chronic severe cardiac failure.
    Currie PJ; Kelly MJ; Middlebrook K; Federman J; Sainsbury E; Ashley J; Pitt A
    Br Heart J; 1984 May; 51(5):530-8. PubMed ID: 6326784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Haemodynamic effects of intravenously administered prenalterol in patients with severe heart failure.
    Waagstein F; Estrada-Yamamoto M; Reiz S; Reyes C; Hjalmarson A
    Acta Med Scand Suppl; 1982; 659():221-31. PubMed ID: 6127891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contractile, coronary, and metabolic effects of the acute and long-term treatment of cardiac failure with prenalterol.
    Strauer BE; Bohn I; Hahn B; Kment A; Motz U
    J Cardiovasc Pharmacol; 1984; 6(3):491-8. PubMed ID: 6202977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamic effects of prenalterol in healthy subjects.
    Johnsson G
    Acta Med Scand Suppl; 1982; 659():109-22. PubMed ID: 6127882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical results with prenalterol in patients with heart failure.
    Waagstein F; Reiz S; Ariniego R; Hjalmarson A
    Am Heart J; 1981 Sep; 102(3 Pt 2):548-54. PubMed ID: 7270401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beta-adrenergic stimulation of the failing ventricle: a double-blind, randomized trial of sustained oral therapy with prenalterol.
    Roubin GS; Choong CY; Devenish-Meares S; Sadick NN; Fletcher PJ; Kelly DT; Harris PJ
    Circulation; 1984 May; 69(5):955-62. PubMed ID: 6142775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hemodynamic, hormonal and electrolyte responses to prenalterol infusion in heart failure.
    Fitzpatrick D; Ikram H; Nicholls MG; Espiner EA
    Circulation; 1983 Mar; 67(3):613-9. PubMed ID: 6821903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of i.v. prenalterol in patients with severe cardiac failure at rest and during exercise.
    Doering W; Wauer B; Isbary J
    Acta Med Scand Suppl; 1982; 659():307-14. PubMed ID: 6127897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hemodynamic effects of intravenous prenalterol in patients on long-term digoxin therapy for congestive heart failure.
    Dahlström U; Karlsson E; Wranne B
    Eur Heart J; 1982 Aug; 3(4):331-8. PubMed ID: 7128622
    [No Abstract]   [Full Text] [Related]  

  • 18. [Long-term effect of a new beta-agonist prenalterol in patients with severe congestive heart failure (author's transl)].
    Lambertz H; Erbel R; Meyer J; Schweizer P; Effert S
    Z Kardiol; 1982 Jan; 71(2):65-74. PubMed ID: 6122313
    [No Abstract]   [Full Text] [Related]  

  • 19. Metabolic effects of prenalterol in diabetic patients.
    Oltmanns D
    Acta Med Scand Suppl; 1982; 659():147-55. PubMed ID: 6127885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Haemodynamic and cardiac metabolic effects of the new beta 1 agonist prenalterol in patients with cardiac failure.
    Kupper W; Schütt M; Hamm CW; Kuck KH; Hanrath P; Bleifeld W
    Eur Heart J; 1983 Aug; 4(8):573-83. PubMed ID: 6139281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.